Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1991-11

AUTHORS

Rainer Enkelmann

ABSTRACT

The efficacy and safety of alprazolam and buspirone for treating generalized anxiety disorder (GAD) were compared in a 6-week, double-blind, randomized, placebo-controlled study of 94 outpatients. Mean daily doses at the end of the study were 1.9 mg alprazolam and 18.7 mg buspirone. As judged by the Hamilton Anxiety Rating Scale, Hamilton Depression Rating Scale, Physician's Global Improvement Scale, and other efficacy scales, alprazolam and buspirone were similar in efficacy, but more effective than placebo, for treating anxiety and depression symptoms in these patients. Clinically important differences were noted between drugs in the onset of effect, with alprazolam producing rapid and sustained improvement within the first week of treatment and buspirone producing more gradual, continuous improvement throughout the study. Significantly more buspirone-treated than alprazolam-treated patients failed to complete the study, primarily because of side effects or inefficacy. No clinically important differences were noted between alprazolam and buspirone in side effects, vital signs, or laboratory test results. Alprazolam-treated patients most frequently reported central nervous system-related side effects (drowsiness and sedation), while buspirone-treated patients most frequently reported gastrointestinal system-related side effects (appetite disturbances and abdominal complaints). More... »

PAGES

428-432

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf02244440

DOI

http://dx.doi.org/10.1007/bf02244440

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1021959027

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1798836


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Alprazolam", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anxiety Disorders", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Buspirone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Psychiatric Status Rating Scales", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Heerstrasse 114, W-5401, St. Goar, Federal Republic of Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Enkelmann", 
        "givenName": "Rainer", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1001/archpsyc.1970.01750020068009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020710273"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.2044-8341.1959.tb00467.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025431669"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archpsyc.1987.01800220024005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025449162"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-198632020-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030918482", 
          "https://doi.org/10.2165/00003495-198632020-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archpsyc.1988.01800290053007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033646090"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00464571", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035511571", 
          "https://doi.org/10.1007/bf00464571"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00464571", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035511571", 
          "https://doi.org/10.1007/bf00464571"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1600-0447.1987.tb02830.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037331227"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/archpsyc.1988.01800290027004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037450716"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/jnnp.23.1.56", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042824373"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/j.1875-9114.1984.tb03327.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048139219"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1176/ajp.140.1.82", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063473697"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1192/bjp.146.5.515", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064168625"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079434982", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000414021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079669891"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079676017", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081574773", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081581561", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081943728", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082481764", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1991-11", 
    "datePublishedReg": "1991-11-01", 
    "description": "The efficacy and safety of alprazolam and buspirone for treating generalized anxiety disorder (GAD) were compared in a 6-week, double-blind, randomized, placebo-controlled study of 94 outpatients. Mean daily doses at the end of the study were 1.9 mg alprazolam and 18.7 mg buspirone. As judged by the Hamilton Anxiety Rating Scale, Hamilton Depression Rating Scale, Physician's Global Improvement Scale, and other efficacy scales, alprazolam and buspirone were similar in efficacy, but more effective than placebo, for treating anxiety and depression symptoms in these patients. Clinically important differences were noted between drugs in the onset of effect, with alprazolam producing rapid and sustained improvement within the first week of treatment and buspirone producing more gradual, continuous improvement throughout the study. Significantly more buspirone-treated than alprazolam-treated patients failed to complete the study, primarily because of side effects or inefficacy. No clinically important differences were noted between alprazolam and buspirone in side effects, vital signs, or laboratory test results. Alprazolam-treated patients most frequently reported central nervous system-related side effects (drowsiness and sedation), while buspirone-treated patients most frequently reported gastrointestinal system-related side effects (appetite disturbances and abdominal complaints).", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf02244440", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1085440", 
        "issn": [
          "0033-3158", 
          "1432-2072"
        ], 
        "name": "Psychopharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "105"
      }
    ], 
    "name": "Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder", 
    "pagination": "428-432", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "689dd1d6c7735b46d0821a8f7b09121d368b9dd619ac4004994622e139595394"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1798836"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7608025"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf02244440"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1021959027"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf02244440", 
      "https://app.dimensions.ai/details/publication/pub.1021959027"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000362_0000000362/records_87082_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2FBF02244440"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf02244440'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf02244440'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf02244440'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf02244440'


 

This table displays all metadata directly associated to this object as RDF triples.

168 TRIPLES      21 PREDICATES      60 URIs      33 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf02244440 schema:about N04c7d1ff73ad4972aafbf2954714080c
2 N3979dc547b054336a969dcdc1f209437
3 N5f2d2d6d9be041b69369c61bcffda202
4 N62fb4dbc7d4f42598ce2952eab164011
5 N6548872b73964a4ea3af3b08f536c1ae
6 N975034ebaa0d49d9aa9c61d7cd89f6b3
7 N9a5656ae84c94affaa144ee198a78840
8 Na6d4e79813f8401cb2075a2f26cc3a91
9 Nbadfe13477e6402990f2a557f13f8a04
10 Ndf02564d816d421493d55eb6ffefdd6a
11 Ne04c28c0128649cc9516a29a7c3caa2d
12 Nf77cc6f528ab4825a09f2bc3f52bd3fd
13 anzsrc-for:11
14 anzsrc-for:1103
15 schema:author Nf93e7875fb164f28b7136ee66f1e6575
16 schema:citation sg:pub.10.1007/bf00464571
17 sg:pub.10.2165/00003495-198632020-00002
18 https://app.dimensions.ai/details/publication/pub.1079434982
19 https://app.dimensions.ai/details/publication/pub.1079676017
20 https://app.dimensions.ai/details/publication/pub.1081574773
21 https://app.dimensions.ai/details/publication/pub.1081581561
22 https://app.dimensions.ai/details/publication/pub.1081943728
23 https://app.dimensions.ai/details/publication/pub.1082481764
24 https://doi.org/10.1001/archpsyc.1970.01750020068009
25 https://doi.org/10.1001/archpsyc.1987.01800220024005
26 https://doi.org/10.1001/archpsyc.1988.01800290027004
27 https://doi.org/10.1001/archpsyc.1988.01800290053007
28 https://doi.org/10.1002/j.1875-9114.1984.tb03327.x
29 https://doi.org/10.1111/j.1600-0447.1987.tb02830.x
30 https://doi.org/10.1111/j.2044-8341.1959.tb00467.x
31 https://doi.org/10.1136/jnnp.23.1.56
32 https://doi.org/10.1159/000414021
33 https://doi.org/10.1176/ajp.140.1.82
34 https://doi.org/10.1192/bjp.146.5.515
35 schema:datePublished 1991-11
36 schema:datePublishedReg 1991-11-01
37 schema:description The efficacy and safety of alprazolam and buspirone for treating generalized anxiety disorder (GAD) were compared in a 6-week, double-blind, randomized, placebo-controlled study of 94 outpatients. Mean daily doses at the end of the study were 1.9 mg alprazolam and 18.7 mg buspirone. As judged by the Hamilton Anxiety Rating Scale, Hamilton Depression Rating Scale, Physician's Global Improvement Scale, and other efficacy scales, alprazolam and buspirone were similar in efficacy, but more effective than placebo, for treating anxiety and depression symptoms in these patients. Clinically important differences were noted between drugs in the onset of effect, with alprazolam producing rapid and sustained improvement within the first week of treatment and buspirone producing more gradual, continuous improvement throughout the study. Significantly more buspirone-treated than alprazolam-treated patients failed to complete the study, primarily because of side effects or inefficacy. No clinically important differences were noted between alprazolam and buspirone in side effects, vital signs, or laboratory test results. Alprazolam-treated patients most frequently reported central nervous system-related side effects (drowsiness and sedation), while buspirone-treated patients most frequently reported gastrointestinal system-related side effects (appetite disturbances and abdominal complaints).
38 schema:genre research_article
39 schema:inLanguage en
40 schema:isAccessibleForFree false
41 schema:isPartOf N26e235e4c9ef401aba220670935214f1
42 Nc76f61bd886c482ea6b1d8acfe115e13
43 sg:journal.1085440
44 schema:name Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder
45 schema:pagination 428-432
46 schema:productId Nb05d12967dba46bca1c79465110b9077
47 Ndfbdf5647b0447609ecad49ab9cc9828
48 Ne5e9b2df38a543c3af71500e6345752f
49 Ned1903b7fe9e4d2a9574279f1af87b1b
50 Nedb97eadac4e459688b39bc7f0788d9d
51 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021959027
52 https://doi.org/10.1007/bf02244440
53 schema:sdDatePublished 2019-04-11T12:21
54 schema:sdLicense https://scigraph.springernature.com/explorer/license/
55 schema:sdPublisher N87eebdc29df04ed3808a54a9303d53fe
56 schema:url http://link.springer.com/10.1007%2FBF02244440
57 sgo:license sg:explorer/license/
58 sgo:sdDataset articles
59 rdf:type schema:ScholarlyArticle
60 N04c7d1ff73ad4972aafbf2954714080c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
61 schema:name Alprazolam
62 rdf:type schema:DefinedTerm
63 N26e235e4c9ef401aba220670935214f1 schema:issueNumber 3
64 rdf:type schema:PublicationIssue
65 N27da547ac6154a8c99f6259d648c0193 schema:name Heerstrasse 114, W-5401, St. Goar, Federal Republic of Germany
66 rdf:type schema:Organization
67 N3979dc547b054336a969dcdc1f209437 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Adult
69 rdf:type schema:DefinedTerm
70 N5f2d2d6d9be041b69369c61bcffda202 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Male
72 rdf:type schema:DefinedTerm
73 N62fb4dbc7d4f42598ce2952eab164011 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Aged
75 rdf:type schema:DefinedTerm
76 N6548872b73964a4ea3af3b08f536c1ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Middle Aged
78 rdf:type schema:DefinedTerm
79 N680b168833d3446d84a9fb68d3ccc633 schema:affiliation N27da547ac6154a8c99f6259d648c0193
80 schema:familyName Enkelmann
81 schema:givenName Rainer
82 rdf:type schema:Person
83 N87eebdc29df04ed3808a54a9303d53fe schema:name Springer Nature - SN SciGraph project
84 rdf:type schema:Organization
85 N975034ebaa0d49d9aa9c61d7cd89f6b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Double-Blind Method
87 rdf:type schema:DefinedTerm
88 N9a5656ae84c94affaa144ee198a78840 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Humans
90 rdf:type schema:DefinedTerm
91 Na6d4e79813f8401cb2075a2f26cc3a91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Anxiety Disorders
93 rdf:type schema:DefinedTerm
94 Nb05d12967dba46bca1c79465110b9077 schema:name readcube_id
95 schema:value 689dd1d6c7735b46d0821a8f7b09121d368b9dd619ac4004994622e139595394
96 rdf:type schema:PropertyValue
97 Nbadfe13477e6402990f2a557f13f8a04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Adolescent
99 rdf:type schema:DefinedTerm
100 Nc76f61bd886c482ea6b1d8acfe115e13 schema:volumeNumber 105
101 rdf:type schema:PublicationVolume
102 Ndf02564d816d421493d55eb6ffefdd6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Female
104 rdf:type schema:DefinedTerm
105 Ndfbdf5647b0447609ecad49ab9cc9828 schema:name dimensions_id
106 schema:value pub.1021959027
107 rdf:type schema:PropertyValue
108 Ne04c28c0128649cc9516a29a7c3caa2d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Psychiatric Status Rating Scales
110 rdf:type schema:DefinedTerm
111 Ne5e9b2df38a543c3af71500e6345752f schema:name doi
112 schema:value 10.1007/bf02244440
113 rdf:type schema:PropertyValue
114 Ned1903b7fe9e4d2a9574279f1af87b1b schema:name nlm_unique_id
115 schema:value 7608025
116 rdf:type schema:PropertyValue
117 Nedb97eadac4e459688b39bc7f0788d9d schema:name pubmed_id
118 schema:value 1798836
119 rdf:type schema:PropertyValue
120 Nf77cc6f528ab4825a09f2bc3f52bd3fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Buspirone
122 rdf:type schema:DefinedTerm
123 Nf93e7875fb164f28b7136ee66f1e6575 rdf:first N680b168833d3446d84a9fb68d3ccc633
124 rdf:rest rdf:nil
125 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
126 schema:name Medical and Health Sciences
127 rdf:type schema:DefinedTerm
128 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
129 schema:name Clinical Sciences
130 rdf:type schema:DefinedTerm
131 sg:journal.1085440 schema:issn 0033-3158
132 1432-2072
133 schema:name Psychopharmacology
134 rdf:type schema:Periodical
135 sg:pub.10.1007/bf00464571 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035511571
136 https://doi.org/10.1007/bf00464571
137 rdf:type schema:CreativeWork
138 sg:pub.10.2165/00003495-198632020-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030918482
139 https://doi.org/10.2165/00003495-198632020-00002
140 rdf:type schema:CreativeWork
141 https://app.dimensions.ai/details/publication/pub.1079434982 schema:CreativeWork
142 https://app.dimensions.ai/details/publication/pub.1079676017 schema:CreativeWork
143 https://app.dimensions.ai/details/publication/pub.1081574773 schema:CreativeWork
144 https://app.dimensions.ai/details/publication/pub.1081581561 schema:CreativeWork
145 https://app.dimensions.ai/details/publication/pub.1081943728 schema:CreativeWork
146 https://app.dimensions.ai/details/publication/pub.1082481764 schema:CreativeWork
147 https://doi.org/10.1001/archpsyc.1970.01750020068009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020710273
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1001/archpsyc.1987.01800220024005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025449162
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1001/archpsyc.1988.01800290027004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037450716
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1001/archpsyc.1988.01800290053007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033646090
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1002/j.1875-9114.1984.tb03327.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1048139219
156 rdf:type schema:CreativeWork
157 https://doi.org/10.1111/j.1600-0447.1987.tb02830.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1037331227
158 rdf:type schema:CreativeWork
159 https://doi.org/10.1111/j.2044-8341.1959.tb00467.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1025431669
160 rdf:type schema:CreativeWork
161 https://doi.org/10.1136/jnnp.23.1.56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042824373
162 rdf:type schema:CreativeWork
163 https://doi.org/10.1159/000414021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079669891
164 rdf:type schema:CreativeWork
165 https://doi.org/10.1176/ajp.140.1.82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063473697
166 rdf:type schema:CreativeWork
167 https://doi.org/10.1192/bjp.146.5.515 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064168625
168 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...